EGFR and non-small cell lung carcinoma: Sensitivity analyses were conducted for OS and PFS, focusing on all NSCLC patients (Figures 4A, 5A), EGFR-TKI-treated patients (Figures 4B, 5B), and diabetic patients (Figures 4C, 5C).